Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Subclinical Inflammation and High Cardiovascular Risk — MicroVasc-DIVA

Type 2 Diabetic Patients Clinical Trial

Official title:
Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Low Dose Aspirin in Type-2 Diabetic Patients With Very High Cardiovascular Risk and Subclinical Inflammation

Status Completed

Clinical Trial Summary

Study to investigate microvascular and antiinflammatory effects of Rivaroxaban compared to low dose aspirin in type 2 diabetic patients. Especially patients with cardiovascular disease and subclinical inflammation are in the focus of interest.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02164578
Study type	Interventional
Source	GWT-TUD GmbH
Contact
Status	Completed
Phase	Phase 3
Start date	April 2015
Completion date	April 30, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03006159` - A Phase 1, Randomized, Placebo-controlled, Multiple Dose Escalation Study to Investigate Safety, Pharmacokinetics, and Pharmacodynamics of SHR0534 in Chinese Type 2 Diabetic Patients	Phase 1
Completed	`NCT01049750` - Prevalence and Risk Factors of Erectile Dysfunction in Type 2 Diabetic Patients	N/A
Not yet recruiting	`NCT03987308` - Comparing the Efficacy and Safety Between Short-term Continuous Subcutaneous Beinaglutide Injection and Continuous Subcutaneous Insulin Infusion (CSII) for Newly Diagnosed Type 2 Diabetes	N/A
Completed	`NCT01049321` - The Effect of DASH Diet on the Cardiometabolic Risks and Hepatic Function Among Type 2 Diabetic Patients	Phase 4
Completed	`NCT00941148` - Beta-Cell Function of Insulin Glargine Compared to Neutral Protamine Hagedorn (NPH) Insuline and to Insulin Detemir in Combination With Metformin	Phase 4